- Causal AI and disease digital twins
- Built specifically for drug discovery teams, not bolt-on AI
- Scales across organization-wide research programs
- Spans multiple major therapeutic areas
- Built directly from human patient data
- Supports discovery through pre-IND development
- Targets causal rather than correlational relationships
Aitia
Causal AI and disease digital twins
SF7.18
SF Score editorial score across features, ease, and value, based on public reviews and product research. Learn more →
Mine literature for research signalsPharma and discovery research partners
Mine literature for research signalsPharma and discovery research partners
Best for
Pharma and discovery research partners
Pricing
Custom
Free plan
Check vendor
SoftFinders Score
7.18 / 10
Overview
What is Aitia?
Aitia is an AI drug discovery company for pharma and research partners, using causal AI and disease digital twins to identify drug targets and biomarkers.
- Research focus: Its causal AI and computational biology approach supports R&D acceleration rather than guaranteed clinical outcomes, with candidates requiring downstream validation.
- Best-fit environment: Pharma and discovery research partners may benefit when disease digital twins fit target discovery and biomarker workflows.
- Engagement model: Access is partnership and research-led rather than self-service, making data access, collaboration structure, and timelines to validated leads key considerations.
- Commercial model: Pricing is sales-led and scoped per buyer rather than publicly posted, while collaboration costs should be assessed before longer programs.
Aitia is best evaluated through a focused pilot that tests one workflow, data requirements, and collaboration needs before broader commitment.
KEY FEATURES
What you get out of the box
Knowledge Graph
Connects biological and chemical knowledge sources
Virtual Screening
Screens compound libraries against targets
Literature Intelligence
Mines biomedical literature for relevant evidence
Multi Omics
Integrates genomic and other omics data sources
Lab Integration
Connects discovery insights with wet-lab workflows
Partner Workflows
Workflows for pharma partner collaborations
Gemini Digital Twins
Models disease from human multiomic and clinical data
Counterfactual Virtual Experiments
Tests gene, protein, and drug perturbations
USE CASES
Where teams put it to work
Mine literature for research signals
Run virtual screens against targets
Collaborate with pharma partners
Bridge AI design and wet lab cycles
Identify drug targets from biology data
Accelerate molecule design cycles
Simulate partner drug candidates preclinically
Explore optimal combination therapies
Validate targets against clinical outcomes
Stratify patients for clinical development
Editorial Take
What we like, and what to verify
- Engagement is partnership and research-led
- Drug success still depends on downstream trials
- Pricing is sales-led and needs scoping upfront
- Disease models require rich patient datasets
Screenshots
A look inside
Alternatives
Tools to consider next
Iktos SF 7.4
Why consider it
Generative chemistry and synthesis planning AI
Cradle SF 7.48
Why consider it
AI protein design for wet labs
Chai Discovery SF 7.28
Why consider it
Molecular structure prediction for discovery research
NOETIK SF 7.1
Why consider it
Spatial biology models for cancer targets
Generate Biomedicines SF 7.68
Why consider it
Generative protein design across modalities
Causaly SF 7.58
Why consider it
Biomedical evidence and reasoning for R&D
USER REVIEWS
Aitia Reviews
Published user reviews are moderated and kept separate from the SoftFinders Score.
No published reviews yet.
Reviews from real users will appear here once published.
Used Aitia?
Share your experience with other buyers.
FAQ